Proceedings of a Nordic von Willebrand Symposium, Mariehamn, Aland, 24-25 September 1998: Von Willebrand disease: An update in the Aland islands

Haemophilia

Volumn 5, Issue SUPPL. 2, 1999, Pages 1-6

  Berntorp, E ^a   Ingerslev, J ^b   Schulman, S ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bleeding disorder; Factor VIII; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

CONFERENCE PAPER; PRIORITY JOURNAL; VON WILLEBRAND DISEASE;

EID: 0032802763     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. von Willebrand EA. Hereditär pseudohemofili. Finska Läkarsällskapets Handl 1926; 67: 7-112.
2. Nilsson IM. The history of von Willebrand disease. Haemophilia 1999; 5 (Suppl. 2): 7-11.
3. von Willebrand EA. Über hereditäre Pseudohämophilie. Acta Med Scand 1931; 67: 521-50.
4. von Willebrand EA. Über ein vererbbares Blutungsübel: Die konstitutionelle Thrombopathie. Dtsch Arch Klin Med 1933; 175: 453-83.
5. Minot G. A familial hemorrhagic condition associated with prolongation of the bleeding time. Am J Med Sci 1928; 175: 301-6.
6. Nilsson IM, Blombäck B, Blombäck M, Svennerud S. Kvinnlig hämofili och dess behandling med humant antihemofiliglobulin. Nord Med 1956; 56: 1654-63.
7. Nilsson IM, Blombäck M, von Francken I. On an inherited autosomal hemorrhagic diathesis with antihemofiliglobulin (AHG) deficiency and prolonged bleeding time. Acta Med Scand 1957; 159: 35-57.
8. Nilsson IM, Blombäck M, Blombäck B. von Willebrand's disease in Sweden. Its pathogenesis and treatment. Acta Med Scand 1959; 164: 263-78.
9. Cornu P, Larrieu MI, Caen J, Bernard J, Maladie de Willebrand. Etude clinique, genetigue et biologique. Nouv Rev Fr Hematol 1961; 1: 231-62.
10. Blombäck M. Scientific visits to the Åland islands. Haemophilia 1999; 5 (Suppl. 2): 12-18.
11. Ginsburg D. The molecular biology of von Willebrand disease. Haemophilia 1999; 5 (Suppl. 2): 19-27.
12. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-5.
13. Ginsburg D, Handin RI, Bonthron DR et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Sci 1985; 228: 1401.
14. Sadler JE, Shelton-Inloes BB, Sorace JM, Harlan JM, Titani K, Davie EW. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci USA 1985; 82: 6394.
15. Verweij CL, de Vries CJM, Distel B et al. Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucl Acids Res 1985; 13: 4699.
16. Lynch DC, Zimmermann TS, Collins CJ et al. Molecular cloning of cDNA for human von Willebrand factor; authentication by a new method. Cell 1985; 41: 49.
17. Mancuso DJ, Tuley EA, Westfield LA et al. Human von Willebrand factor gene and pseudogene: Structural analysis and differentation by polymerase chain reaction. Biochem 1991; 30: 253.
18. Mohlke KL, Ginsburg D. von Willebrand disease and quantitative deficiency of von Willebrand factor. J Lab Clin Med 1997; 130: 252.
19. Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985; 37: 89.
20. Holmberg L, Lethagen S. Classification of von Willebrand disease - emerging issues. Haemophilia 1999; 5 (Suppl. 2): 46-49.
21. Hilbert L, Gaucher C, Mazurier C. Identification of two mutations (Arg611Cys and Arg611His) in the Al loop of von Willebrand factor (vWF) responsible for type 2 von Willebrand disease with decreased platelet dependent function of vWF. Blood 1995; 86: 1010-8.
22. Federici AB, Mannucci PM. Diagnosis and management of von Willebrand disease. Haemophilia 1999; 5 (Suppl. 2): 28-37.
23. Ingerslev J, Gürsel T. Diagnosis of von Willebrand disease. Haemophilia 1999; 5 (Suppl. 2): 50-56.
24. Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in school children: a multiethnic study. J Pediatr 1993; 123: 893-8.
25. Lee CA. Women and von Willebrand disease. Haemophilia 1999; 5 (Suppl. 2): 38-45.
26. Royal College of General Practitioners, Office of Population Censuses, Surveys Department of Health and Social Security. Morbidity statistics from general practice. Third national study 1981-82 Series MBS No 1. London: HMSO. 1986.
27. Bradlow J, Coulter A, Brooks P. Patterns of Referral. Oxford: Health Services Research Unit 1992.
28. Edlund M, Blombäck M, von Schoultz B, Andersson O. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 1996; 53: 234-8.
29. Lethagen S. Haemostatic treatment in connection with surgery in patients with von Willebrand disease. Haemophilia 1999; 5 (Suppl. 2): 64-67.
30. Berntorp E. von Willebrand factor-containing factor VIII concentrates. Haemophilia 1999; 5 (Suppl. 2): 60-63.
31. Schulman S. Haemostatic and replacement therapy in von Willebrand disease. Haemophilia 1999; 5 (Suppl. 2): 57-59.
32. Berntorp E, Nilsson IM. Use of a high purity factor VIII concentrate (Hemate P) in von Willebrand disease. Vox Sang 1989; 56: 212-7.
33. Goudemand J, Mazurier C, Marey A et al. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity. Br J Haematol 1992; 80: 214-21.
34. Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III. Ann Hematol 1992; 65: 253-9.
35. Ciavarella N, Schiavoni M, Valkenzano M, Mangini F, Inchingolo F. Use of recombinant factor VIIa (NovoSeven®) in the treatment of two patients with type III von Willebrand disease and an inhibitor against von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis 1996; 26(Suppl. 1): 150-4.
36. Menache D, Aronsen DL. New treatments of von Willebrand disease: Plasma derived von Willebrand factor concentrates. Thromb Haemost 1997; 78: 566-70.
37. Kekomäki R, Rasi V, Ebeling F et al. von Willebrand disease in Finland. Haemophilia 1999; 5(Suppl. 2): 72.
38. Scheibel E. von Willebrand disease in Sweden: demography and treatment. Haemophilia 1999; 5(Suppl. 2): 71.
39. Glomstein A. von Willebrand disease in Norway. Haemophilia 1999; 5(Suppl. 2): 70.
40. Tengborn L. von Willebrand disease in Sweden: demography and treatment. Haemophilia 1999; 5 (Suppl. 2): 75-76.
41. Petrini E. Acquired von Willebrand disease. Haemophilia 1999; 5(Suppl. 2): 68.